101 research outputs found
The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases
Introduction: psychoactive substances are associated with the idea of drugs with high addictive
liability, affecting mental states, cognition, emotion and motor behavior. However these
substances can modify synaptic transmission and help to disclose some mechanisms underlying
alterations in brain processing and pathophysiology of motor disease. Hence, the “bright side” of
e cannabinoid-based drugs must be thoroughly examined to be identified within the latter
framework.
Areas covered: we will analyze the preclinical and clinical evidence of cannabinoid-based drugs,
discussing their therapeutic value in basal ganglia motor disorders such as Parkinson’s disease
and Huntington disease.
Expert commentary: despite the knowledge acquired in the last years, the therapeutic potential of
cannabinoid-based drugs should be further tested by novel routes of investigation. This should be
focused on the role of cannabinoid signaling system in mitochondrial function as well as on the
physical and functional interaction with other key receptorial targets belonging to this network
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease
Alterations of the dopaminergic (DAergic) system are frequently reported in Alzheimer’s disease (AD) patients and are commonly linked to cognitive and non-cognitive symptoms. However, the cause of DAergic system dysfunction in AD remains to be elucidated. We investigated alterations of the midbrain DAergic system in the Tg2576 mouse model of AD, overexpressing a mutated human amyloid precursor protein (APPswe). Here, we found an age-dependent DAergic neuron loss in the ventral tegmental area (VTA) at pre-plaque stages, although substantia nigra pars compacta (SNpc) DAergic neurons were intact. The selective VTA DAergic neuron degeneration results in lower DA outflow in the hippocampus and nucleus accumbens (NAc) shell. The progression of DAergic cell death correlates with impairments in CA1 synaptic plasticity, memory performance and food reward processing. We conclude that in this mouse model of AD, degeneration of VTA DAergic neurons at pre-plaque stages contributes to memory deficits and dysfunction of reward processing
Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation
The success of antipsychotic drug treatment in patients with schizophrenia is limited by the propensity of these drugs to induce hyperphagia, weight gain and other metabolic disturbances, particularly evident for olanzapine and clozapine. However, the molecular mechanisms involved in antipsychotic-induced hyperphagia remain unclear. Here, we investigate the effect of olanzapine administration on the regulation of hypothalamic mechanisms controlling food intake, namely neuropeptide expression and AMP-activated protein kinase (AMPK) phosphorylation in rats. Our results show that subchronic exposure to olanzapine upregulates neuropeptide Y (NPY) and agouti related protein (AgRP) and downregulates proopiomelanocortin (POMC) in the arcuate nucleus of the hypothalamus (ARC). This effect was evident both in rats fed ad libitum and in pair-fed rats. Of note, despite weight gain and increased expression of orexigenic neuropeptides, subchronic administration of olanzapine decreased AMPK phosphorylation levels. This reduction in AMPK was not observed after acute administration of either olanzapine or clozapine. Overall, our data suggest that olanzapine-induced hyperphagia is mediated through appropriate changes in hypothalamic neuropeptides, and that this effect does not require concomitant AMPK activation. Our data shed new light on the hypothalamic mechanism underlying antipsychotic-induced hyperphagia and weight gain, and provide the basis for alternative targets to control energy balance
Postnatal Aversive Experience Impairs Sensitivity to Natural Rewards and Increases Susceptibility to Negative Events in Adult Life
Evidence shows that maternal care and postnatal traumatic events
can exert powerful effects on brain circuitry development but little
is known about the impact of early postnatal experiences on processing
of rewarding and aversive stimuli related to the medial prefrontal
cortex (mpFC) function in adult life. In this study, the
unstable maternal environment induced by repeated cross-fostering
(RCF) impaired palatable food conditioned place preference and disrupted
the natural preference for sweetened fluids in the saccharin
preference test. By contrast, RCF increased sensitivity to conditioned
place aversion (CPA) and enhanced immobility in the
forced swimming test. Intracerebral microdialysis data showed that
the RCF prevents mpFC dopamine (DA) outflow regardless of
exposure to rewarding or aversive stimuli, whereas it induces a
strong and sustained prefrontal norepinephrine (NE) release in
response to different aversive experiences. Moreover, the selective
mpFC NE depletion abolished CPA, thus indicating that prefrontal
NE is required for motivational salience attribution to aversionrelated
stimuli. These findings demonstrate that an unstable
maternal environment impairs the natural propensity to seek pleasurable
sources of reward, enhances sensitivity to negative events
in adult life, blunts prefrontal DA outflow, and modulates NE release
in the reverse manner depending on the exposure to rewarding or
aversive stimuli
Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s Disease
Retina and optic nerve are sites of extra-cerebral manifestations of Alzheimer’s Disease (AD). Amyloid-β (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau protein are detected in eyes from AD patients and transgenic animals in correlation with inflammation, reduction of synapses, visual deficits, loss of retinal cells and nerve fiber. However, neither the pathological relevance of other post-translational tau modifications—such as truncation with generation of toxic fragments—nor the potential neuroprotective action induced by their in vivo clearance have been investigated in the context of AD retinal degeneration. We have recently developed a monoclonal tau antibody (12A12mAb) which selectively targets the neurotoxic 20–22 kDa NH2-derived peptide generated from pathological truncation at the N-terminal domain of tau without cross-reacting with its full-length normal protein. Previous studies have shown that 12A12mAb, when intravenously (i.v.)-injected into 6-month-old Tg2576 animals, markedly improves their AD-like, behavioural and neuropathological syndrome. By taking advantage of this well-established tau-directed immunization regimen, we found that 12A12mAb administration also exerts a beneficial action on biochemical, morphological and metabolic parameters (i.e. APP/Aβ processing, tau hyperphosphorylation, neuroinflammation, synaptic proteins, microtubule stability, mitochondria-based energy production, neuronal death) associated with ocular injury in the AD phenotype. These findings prospect translational implications in the AD field by: (1) showing for the first time that cleavage of tau takes part in several pathological changes occurring in vivo in affected retinas and vitreous bodies and that its deleterious effects are successfully antagonized by administration of the specific 12A12mAb; (2) shedding further insights on the tight connections between neurosensory retina and brain, in particular following tau-based immunotherapy. In our view, the parallel response we detected in this preclinical animal model, both in the eye and in the hippocampus, following i.v. 12A12mAb injection opens novel diagnostic and therapeutic avenues for the clinical management of cerebral and extracerebral AD signs in human beings
Satiety factor oleoylethanolamide recruits the brain histaminergic system to inhibit food intake
Effects of caloric restriction on neuropathic pain, peripheral nerve degeneration and inflammation in normometabolic and autophagy defective prediabetic Ambra1 mice
There is a growing interest on the role of autophagy in diabetes pathophysiology, where development of neuropathy is one of the most frequent comorbidities. We have previously demonstrated that neuropathic pain after nerve damage is exacerbated in autophagy-defective heterozygous Ambra1 mice. Here, we show the existence of a prediabetic state in Ambra1 mice, characterized by hyperglycemia, intolerance to glucose and insulin resistance. Thus, we further investigate the hypothesis that prediabetes may account for the exacerbation of allodynia and chronic pain and that counteracting the autophagy deficit may relieve the neuropathic condition. We took advantage from caloric restriction (CR) able to exert a double action: a powerful increase of autophagy and a control on the metabolic status. We found that CR ameliorates neuropathy throughout anti-inflammatory and metabolic mechanisms both in Ambra1 and in WT animals subjected to nerve injury. Moreover, we discovered that nerve lesion represents, per se, a metabolic stressor and CR reinstates glucose homeostasis, insulin resistance, incomplete fatty acid oxidation and energy metabolism. As autophagy inducer, CR promotes and anticipates Schwann cell autophagy via AMP-activated protein kinase (AMPK) that facilitates remyelination in peripheral nerve. In summary, we provide new evidence for the role of autophagy in glucose metabolism and identify in energy depletion by dietary restriction a therapeutic approach in the fight against neuropathic pain
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease
Alterations of the dopaminergic (DAergic) system are frequently reported in Alzheimer's disease (AD) patients and are commonly linked to cognitive and non-cognitive symptoms. However, the cause of DAergic system dysfunction in AD remains to be elucidated. We investigated alterations of the midbrain DAergic system in the Tg2576 mouse model of AD, overexpressing a mutated human amyloid precursor protein (APPswe). Here, we found an age-dependent DAergic neuron loss in the ventral tegmental area (VTA) at pre-plaque stages, although substantia nigra pars compacta (SNpc) DAergic neurons were intact. The selective VTA DAergic neuron degeneration results in lower DA outflow in the hippocampus and nucleus accumbens (NAc) shell. The progression of DAergic cell death correlates with impairments in CA1 synaptic plasticity, memory performance and food reward processing. We conclude that in this mouse model of AD, degeneration of VTA DAergic neurons at pre-plaque stages contributes to memory deficits and dysfunction of reward processing
Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse AD models
Clinical and neuropathological studies have shown that tau pathology better correlates with the severity of dementia than amyloid plaque burden, making tau an attractive target for the cure of Alzheimer\u2019s disease. We have explored whether passive immunization with the 12A12 monoclonal antibody (26\u201336aa of tau protein) could improve the Alzheimer\u2019s disease phenotype of two well-established mouse models, Tg2576 and 3xTg mice. 12A12 is a cleavage-specific monoclonal antibody which selectively binds the pathologically relevant neurotoxic NH226-230 fragment (i.e. NH2htau) of tau protein without cross-reacting with its full-length physiological form(s). We found out that intravenous administration of 12A12 monoclonal antibody into symptomatic (6 months old) animals: (i) reaches the hippocampus in its biologically active (antigen-binding competent) form and successfully neutralizes its target; (ii) reduces both pathological tau and amyloid precursor protein/amyloid\u3b2 metabolisms involved in early disease-associated synaptic deterioration; (iii) improves episodic-like type of learning/memory skills in hippocampal-based novel object recognition and object place recognition behavioural tasks; (iv) restores the specific up-regulation of the activity-regulated cytoskeleton-associated protein involved in consolidation of experience-dependent synaptic plasticity; (v) relieves the loss of dendritic spine connectivity in pyramidal hippocampal CA1 neurons; (vi) rescues the Alzheimer\u2019s disease-related electrophysiological deficits in hippocampal long-term potentiation at the CA3-CA1 synapses; and (vii) mitigates the neuroinflammatory response (reactive gliosis). These findings indicate that the 20\u201322 kDa NH2-terminal tau fragment is crucial target for Alzheimer\u2019s disease therapy and prospect immunotherapy with 12A12 monoclonal antibody as safe (normal tau-preserving), beneficial approach in contrasting the early Amyloid\u3b2-dependent and independent neuropathological and cognitive alterations in affected subject
Histone Modifications in a Mouse Model of Early Adversities and Panic Disorder: Role for Asic1 and Neurodevelopmental Genes
Hyperventilation following transient, CO2-induced acidosis is ubiquitous in mammals and heritable.
In humans, respiratory and emotional hypersensitivity to CO2 marks separation anxiety and panic
disorders, and is enhanced by early-life adversities. Mice exposed to the repeated cross-fostering
paradigm (RCF) of interference with maternal environment show heightened separation anxiety and
hyperventilation to 6% CO2-enriched air. Gene-environment interactions affect CO2 hypersensitivity
in both humans and mice. We therefore hypothesised that epigenetic modifications and increased
expression of genes involved in pH-detection could explain these relationships. Medullae oblongata
of RCF- and normally-reared female outbred mice were assessed by ChIP-seq for H3Ac, H3K4me3,
H3K27me3 histone modifications, and by SAGE for differential gene expression. Integration of multiple
experiments by network analysis revealed an active component of 148 genes pointing to the mTOR
signalling pathway and nociception. Among these genes, Asic1 showed heightened mRNA expression,
coherent with RCF-mice’s respiratory hypersensitivity to CO2 and altered nociception. Functional
enrichment and mRNA transcript analyses yielded a consistent picture of enhancement for several
genes affecting chemoception, neurodevelopment, and emotionality. Particularly, results with Asic1
support recent human findings with panic and CO2 responses, and provide new perspectives on how
early adversities and genes interplay to affect key components of panic and related disorders
- …